This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


reputable news agency


Sanofi says to reach settlement on Zantac lawsuits in US

Credit: Pixabay/CC0 Public Domain

French pharmaceutical giant Sanofi said Thursday it had reached a preliminary agreement on settling thousands of US lawsuits concerning its heartburn drug Zantac.

A spokesman said that all bodily injury claims except for those before courts in the US state of Delaware were covered under the preliminary deal reached last month.

"This will resolve up to around 4,000 claims" but would take some time to finalize as each claimant would need to agree to the proposed settlement, he added.

Sanofi pulled the over-the-counter heartburn medication Zantac from shelves in the United States and Canada in 2019 after a possible carcinogen was detected.

The Sanofi spokesman said the company was settling not because it believes the cancer claims to be founded "but more to avoid the expense and continual distraction of lawsuits".

British pharmaceutical group GlaxoSmithKline, which also marketed Zantac in the United States, also reached a settlement last year without admitting liability.

The amount of the settlement was not disclosed, but the Sanofi spokesman said it reflected the limited period the company marketed Zantac as well as its strong legal defense arguments.

The company said the would not have a significant financial impact.

Sanofi shares rose 0.4 percent in afternoon trading in Paris, while the blue-chip CAC 40 index was up less than 0.1 percent.

© 2024 AFP

Citation: Sanofi says to reach settlement on Zantac lawsuits in US (2024, April 4) retrieved 25 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Drugmaker settles US Zantac cancer case


Feedback to editors